Favipiravir (T-705) inhibits in vitro norovirus replication

Rocha-Pereira, J., Jochmans, D., Dallmeier, K., Leyssen, P., Nascimento, M. S. J., & Neyts, J.

Biochemical and biophysical research communications 424.4 (2012): 777-780.

Human noroviruses are the primary cause of foodborne gastroenteritis. Potent and safe inhibitors are needed for the treatment/prophylaxis of norovirus infections. We demonstrate that Favipiravir [T-705, a drug in advanced clinical development for the treatment of infections with the influenza virus] inhibits in vitro murine norovirus replication. Time-of-drug addition studies reveal that T-705 exerts its activity at a time-point that coincides with onset of viral RNA synthesis, which is in line with the viral polymerase as the presumed target.

Favipiravir-T-705-inhibits-in-vitro-norovirus-replication

Products Used in this Publication

Catalog NumberCASProduct NamePrice
B0084-463609259793-96-9T 705Inquiry

Related Products

Catalog NumberCASProduct NamePrice
B0084-09403453-84-9NAD+Inquiry
B0084-4566031037624-75-1BemcentinibInquiry
B0084-4627081146963-51-0J 147Inquiry
B0084-4749631015474-32-4CC122Inquiry